1887

Journal of General Virology header logo

Volume 98, Issue 5

Putative roles as oncogene or tumour suppressor of the Mid-clustered microRNAs in (GaHV2) induced Marek’s disease lymphomagenesis Open Access

Abstract

In the last decade, numerous microRNAs (miRNAs) have been identified in diverse virus families, particularly in herpesviruses. (GaHV2) is a representative oncogenic alphaherpesvirus that induces rapid-onset T-cell lymphomas in its natural hosts, namely Marek’s disease (MD). In the GaHV2 genome there are 26 mature miRNAs derived from 14 precursors assembled into three clusters, namely the Meq-cluster, Mid-cluster and LAT-cluster. Several GaHV2 miRNAs, especially those in the Meq-cluster (e.g. miR-M4-5p), have been demonstrated to be critical in MD pathogenesis and/or tumorigenesis. Interestingly the downstream Mid-cluster is regulated and transcribed by the same promoter as the Meq-cluster in the latent phase of the infection, but the role of these Mid-clustered miRNAs in GaHV2 biology remains unclear. We have generated the deletion mutants of the Mid-cluster and of its associated individual miRNAs in GX0101 virus, a very virulent GaHV2 strain, and demonstrated that the Mid-clustered miRNAs are not essential for virus replication. Using GaHV2-infected chickens as an animal model, we found that, compared with parental GX0101 virus, the individual deletion of miR-M31 decreased the mortality and gross tumour incidence of infected chickens while the deletion individually of miR-M1 or miR-M11 unexpectedly increased viral pathogenicity or oncogenicity, similarly to the deletion of the entire Mid-cluster region. More importantly, our data further confirm that miR-M11-5p, the miR-M11-derived mature miRNA, targets the viral oncogene and suppresses its expression in GaHV2 infection. We report here that members of the Mid-clustered miRNAs, miR-M31-3p and miR-M11-5p, potentially act either as oncogene or tumour suppressor in MD lymphomagenesis.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): GaHV2 , herpesvirus , Marek's disease virus , miR-155 , miRNA , oncogene and tumour suppressor
© 2017 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000786
2017-05-01
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/5/1097.html?itemId=/content/journal/jgv/10.1099/jgv.0.000786&mimeType=html&fmt=ahah

References

  1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281–297[PubMed] [CrossRef]
     [Google Scholar]
  2. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136:215–233 [View Article][PubMed]
     [Google Scholar]
  3. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009; 4:199–227 [View Article][PubMed]
     [Google Scholar]
  4. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39:D152–D157 [View Article][PubMed]
     [Google Scholar]
  5. Boss IW, Plaisance KB, Renne R. Role of virus-encoded microRNAs in herpesvirus biology. Trends Microbiol 2009; 17:544–553 [View Article][PubMed]
     [Google Scholar]
  6. Grundhoff A, Sullivan CS. Virus-encoded microRNAs. Virology 2011; 411:325–343 [View Article][PubMed]
     [Google Scholar]
  7. Morgan RW, Burnside J. Roles of avian herpesvirus microRNAs in infection, latency, and oncogenesis. Biochim Biophys Acta 2011; 1809:654–665 [View Article][PubMed]
     [Google Scholar]
  8. Kincaid RP, Sullivan CS. Virus-encoded microRNAs: an overview and a look to the future. PLoS Pathog 2012; 8:e1003018 [View Article][PubMed]
     [Google Scholar]
  9. Davison AJ, Eberle R, Ehlers B, Hayward GS, McGeoch DJ et al. The order Herpesvirales. Arch Virol 2009; 154:171–177 [View Article][PubMed]
     [Google Scholar]
  10. Davison F, Nair V. Marek’s Disease, an Evolving Problem Oxford: Elsevier Academic Press; 2004
     [Google Scholar]
  11. Schat KA, Nair V. Marek’s Disease. In Swayne DE, Glisson JR, McDougald LR, Nolan LK, Suarez DL. et al. (editors) Diseases of Poultry Wiley-Blackwell; 2013 pp. 513–674
     [Google Scholar]
  12. Osterrieder N, Kamil JP, Schumacher D, Tischer BK, Trapp S. Marek's disease virus: from miasma to model. Nat Rev Microbiol 2006; 4:283–294 [View Article][PubMed]
     [Google Scholar]
  13. Calnek BW. Pathogenesis of Marek’s disease virus infection. Current Topics Microbiol Immunol 2001; 255:25–55
     [Google Scholar]
  14. Baigent SJ, Davison F. Marek’s disease virus: biology and life cycle. In Davison F, Nair V. (editors) Marek’s Disease, an Evolving Problem Oxford: Elsevier Academic Press; 2004 pp. 62–77
     [Google Scholar]
  15. Tulman ER, Afonso CL, Lu Z, Zsak L, Rock DL et al. The genome of a very virulent Marek's disease virus. J Virol 2000; 74:7980–7988 [View Article][PubMed]
     [Google Scholar]
  16. Su S, Cui N, Cui Z, Zhao P, Li Y et al. Complete genome sequence of a recombinant Marek's disease virus field strain with one reticuloendotheliosis virus long terminal repeat insert. J Virol 2012; 86:13818–13819 [View Article][PubMed]
     [Google Scholar]
  17. Nair V, Kung HJ. Marek’s disease virus oncogenicity: molecular mechanisms. In Davison F, Nair V. (editors) Marek’s Disease, an Evolving Problem Oxford: Elsevier Academic Press; 2004 pp. 32–48
     [Google Scholar]
  18. Burnside J, Bernberg E, Anderson A, Lu C, Meyers BC et al. Marek's disease virus encodes MicroRNAs that map to meq and the latency-associated transcript. J Virol 2006; 80:8778–8786 [View Article][PubMed]
     [Google Scholar]
  19. Yao Y, Zhao Y, Xu H, Smith LP, Lawrie CH et al. MicroRNA profile of Marek's disease virus-transformed T-cell line MSB-1: predominance of virus-encoded microRNAs. J Virol 2008; 82:4007–4015 [View Article][PubMed]
     [Google Scholar]
  20. Luo J, Teng M, Fan J, Wang F, Zhou L et al. Marek's disease virus-encoded microRNAs: genomics, expression and function. Sci China Life Sci 2010; 53:1174–1180 [View Article][PubMed]
     [Google Scholar]
  21. Gottwein E, Mukherjee N, Sachse C, Frenzel C, Majoros WH et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature 2007; 450:1096–1099 [View Article][PubMed]
     [Google Scholar]
  22. Zhao Y, Yao Y, Xu H, Lambeth L, Smith LP et al. A functional MicroRNA-155 ortholog encoded by the oncogenic Marek's disease virus. J Virol 2009; 83:489–492 [View Article][PubMed]
     [Google Scholar]
  23. Muylkens B, Coupeau D, Dambrine G, Trapp S, Rasschaert D. Marek's disease virus microRNA designated Mdv1-pre-miR-M4 targets both cellular and viral genes. Arch Virol 2010; 155:1823–1837 [View Article][PubMed]
     [Google Scholar]
  24. Tili E, Croce CM, Michaille JJ. miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 2009; 28:264–284 [View Article][PubMed]
     [Google Scholar]
  25. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 2009; 1792:497–505 [View Article][PubMed]
     [Google Scholar]
  26. Zhao Y, Xu H, Yao Y, Smith LP, Kgosana L et al. Critical role of the virus-encoded microRNA-155 ortholog in the induction of Marek's disease lymphomas. PLoS Pathog 2011; 7:e1001305 [View Article][PubMed]
     [Google Scholar]
  27. Yu ZH, Teng M, Sun AJ, Yu LL, Hu B et al. Virus-encoded miR-155 ortholog is an important potential regulator but not essential for the development of lymphomas induced by very virulent Marek's disease virus. Virology 2014; 448:55–64 [View Article][PubMed]
     [Google Scholar]
  28. Chi JQ, Teng M, Yu ZH, Xu H, Su JW et al. Marek's disease virus-encoded analog of microRNA-155 activates the oncogene c-Myc by targeting LTBP1 and suppressing the TGF-β signaling pathway. Virology 2015; 476:72–84 [View Article][PubMed]
     [Google Scholar]
  29. Xu S, Xue C, Li J, Bi Y, Cao Y. Marek's disease virus type 1 microRNA miR-M3 suppresses cisplatin-induced apoptosis by targeting Smad2 of the transforming growth factor beta signal pathway. J Virol 2011; 85:276–285 [View Article][PubMed]
     [Google Scholar]
  30. Teng M, Yu ZH, Sun AJ, Min YJ, Chi JQ et al. The significance of the individual Meq-clustered miRNAs of Marek's disease virus in oncogenesis. J Gen Virol 2015; 96:637–649 [View Article][PubMed]
     [Google Scholar]
  31. Coupeau D, Dambrine G, Rasschaert D. Kinetic expression analysis of the cluster mdv1-mir-M9-M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek's disease virus infection. J Gen Virol 2012; 93:1519–1529 [View Article][PubMed]
     [Google Scholar]
  32. Sun A, Lawrence P, Zhao Y, Li Y, Nair VK et al. A BAC clone of MDV strain GX0101 with REV-LTR integration retained its pathogenicity. Chin Sci Bull 2009; 54:2641–2647 [View Article]
     [Google Scholar]
  33. Morgan R, Anderson A, Bernberg E, Kamboj S, Huang E et al. Sequence conservation and differential expression of Marek's disease virus microRNAs. J Virol 2008; 82:12213–12220 [View Article][PubMed]
     [Google Scholar]
  34. Lambeth LS, Yao Y, Smith LP, Zhao Y, Nair V. MicroRNAs 221 and 222 target p27Kip1 in Marek's disease virus-transformed tumour cell line MSB-1. J Gen Virol 2009; 90:1164–1171 [View Article][PubMed]
     [Google Scholar]
  35. Schat KA, Hooft van Iddekinge BJ, Boerrigter H, O'Connell PH, Koch G. Open reading frame L1 of Marek's disease herpesvirus is not essential for in vitro and in vivo virus replication and establishment of latency. J Gen Virol 1998; 79:841–849 [View Article][PubMed]
     [Google Scholar]
  36. Jarosinski KW, Osterrieder N, Nair VK, Schat KA. Attenuation of Marek's disease virus by deletion of open reading frame RLORF4 but not RLORF5a. J Virol 2005; 79:11647–11659 [View Article][PubMed]
     [Google Scholar]
  37. Luo J, Sun AJ, Teng M, Zhou H, Cui ZZ et al. Expression profiles of microRNAs encoded by the oncogenic Marek's disease virus reveal two distinct expression patterns in vivo during different phases of disease. J Gen Virol 2011; 92:608–620 [View Article][PubMed]
     [Google Scholar]
  38. Zhao P, Li XJ, Teng M, Dang L, Yu ZH et al. In vivo expression patterns of microRNAs of Gallid herpesvirus 2 (GaHV-2) during the virus life cycle and development of Marek's disease lymphomas. Virus Genes 2015; 50:245–252 [View Article][PubMed]
     [Google Scholar]
  39. Parnas O, Corcoran DL, Cullen BR. Analysis of the mRNA targetome of microRNAs expressed by Marek's disease virus. MBio 2014; 5:e01060-13 [View Article][PubMed]
     [Google Scholar]
  40. Strassheim S, Stik G, Rasschaert D, Laurent S. mdv1-miR-M7-5p, located in the newly identified first intron of the latency-associated transcript of Marek's disease virus, targets the immediate-early genes ICP4 and ICP27. J Gen Virol 2012; 93:1731–1742 [View Article][PubMed]
     [Google Scholar]
  41. Yu ZH, Teng M, Luo J, Wang XW, Ding K et al. Molecular characteristics and evolutionary analysis of field Marek's disease virus prevalent in vaccinated chicken flocks in recent years in China. Virus Genes 2013; 47:282–291 [View Article][PubMed]
     [Google Scholar]
  42. Muyrers JP, Zhang Y, Testa G, Stewart AF. Rapid modification of bacterial artificial chromosomes by ET-recombination. Nucleic Acids Res 1999; 27:1555–1557 [View Article][PubMed]
     [Google Scholar]
  43. Narayanan K, Williamson R, Zhang Y, Stewart AF, Ioannou PA. Efficient and precise engineering of a 200 kb β-globin human/bacterial artificial chromosome in E. coli DH10B using an inducible homologous recombination system. Gene Ther 1999; 6:442–447 [View Article][PubMed]
     [Google Scholar]
  44. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 2000; 97:6640–6645 [View Article][PubMed]
     [Google Scholar]
  45. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004; 10:1507–1517 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000786
Loading
Putative roles as oncogene or tumour suppressor of the Mid-clustered microRNAs in Gallid alphaherpesvirus 2 (GaHV2) induced Marek’s disease lymphomagenesis
J. Gen. Virol. 98, 1097 (2017); https://doi.org/10.1099/jgv.0.000786
/content/journal/jgv/10.1099/jgv.0.000786
/content/journal/jgv/10.1099/jgv.0.000786
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error